investors

Press Releases

DateTitle and SummaryView
December 17, 2014
LOS ANGELES , Dec. 17, 2014 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. (" ImmunoCellular ") (NYSE MKT: IMUC) announced that the US Patent and Trademark Office (USPTO) has issued a key patent covering ImmunoCellular's product candidate ICT-107, a dendritic cell-based immunotherapeutic vaccine
ImmunoCellular Therapeutics Announces Issuance of Key Patent For ICT-107 Cancer Vaccine
December 1, 2014
LOS ANGELES , Dec. 1, 2014 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. (" ImmunoCellular ") ( NYSE MKT : IMUC) today announced that the European Medicines Agency (EMA) has provided scientific advice supportive of advancing ICT-107 to a registrational phase III program in patients with newly
ImmunoCellular Therapeutics Receives Positive Regulatory Feedback from European Medicines Agency on Advancing ICT-107 to Phase III Program
November 14, 2014
Continued Positive Trends in Overall Survival and Progression-Free Survival;
Phase 3 Registration Program Anticipated to Start 1H15;
Company to Host Conference Call on Tuesday, November 18th
ImmunoCellular Therapeutics Presents Updated ICT-107 Phase II Data at the Society for Neuro-Oncology Annual Meeting 2014
November 10, 2014
LOS ANGELES , Nov. 10, 2014 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. (" ImmunoCellular ") ( NYSE MKT : IMUC) today announced financial results for the quarter ended September 30, 2014 .  For the quarter ended September 30, 2014 , the Company incurred a net loss of $1.9 million or $0.03 per
ImmunoCellular Therapeutics Announces Third Quarter 2014 Financial Results
September 26, 2014
LOS ANGELES , Sept. 26, 2014 /PRNewswire/ --  ImmunoCellular Therapeutics, Ltd. (" ImmunoCellular ") ( NYSE MKT : IMUC) today announced that Andrew Gengos , Chief Executive Officer, will present a corporate overview and business update at the Livingston Securities 7 th Annual Life Sciences
ImmunoCellular Therapeutics to Present at Livingston Securities Conference on October 1, 2014
September 24, 2014
Ex-Vivo Manipulation of Autologous Hematopoietic Stem Cells Complements Dendritic Cell-based Vaccine Platform; Potential to Develop Single-Agent and Combination Immunotherapeutics
ImmunoCellular Therapeutics Expands Cancer Immunotherapy Platform with Antigen-Specific T-cell Technology Licensed from Caltech
September 17, 2014
ICT-107 Phase II Update Selected for Oral Presentation at Society for Neuro-Oncology Meeting in November; ICT-121 and ICT-140 Programs on Track
ImmunoCellular Therapeutics Receives Positive Regulatory Feedback on ICT-107 Supporting Advancement to Registrational Phase III Testing in Newly Diagnosed Glioblastoma
August 7, 2014
Conference Call Today at 5:00 pm ET
ImmunoCellular Therapeutics Announces Second Quarter 2014 Financial Results
July 29, 2014
LOS ANGELES , July 29, 2014 /PRNewswire/ --  ImmunoCellular Therapeutics, Ltd. (" ImmunoCellular ") (NYSE MKT: IMUC) today announced that it plans to report second quarter 2014 financial results on Thursday, August 7, 2014 . ImmunoCellular will host a conference call and webcast to discuss its
ImmunoCellular Therapeutics to Report Financial Results for the Second Quarter 2014 on August 7, 2014
June 1, 2014
Pre-specified MGMT and HLA Subgroup Analyses Show Potentially Clinically Meaningful Survival Advantages for ICT-107 Treated Patients
Previously Reported Total Population Overall Survival and Progression-Free Survival Rates Sustained
Data Support Rationale for Phase III; US and EU Regulatory Meetings to Discuss Registration Strategy Planned for 3Q14
ImmunoCellular Therapeutics Presents Updated ICT-107 Phase II Data in Patients with Newly Diagnosed Glioblastoma at the 2014 ASCO Annual Meeting
Copyright 2018 by Immunocellular Therapeutics, Ltd.
All Rights Reserved